Proboxis Bio, an Australian biotechnology company working on vaccines against mosquito-borne flaviviruses, has raised $1.5M from Biointelect Pty Ltd Venturer.
The company is advancing ISVacâ„¢, a vaccine platform that originated from research at The University of Queensland. Proboxis Bio says it works with scientific and industry partners to translate that research into new vaccines with potential public health impact, and is focused on building partnerships to support the platform's future development and commercialisation.

















